Point of Care & Home Safety
Point of Care
.. for Clinicians that require immediate and precise results ..
Diagnostics
Clinical Diagnostic
Our In – Vitro Diagnostic (IVD) solutions in a Nutshell.
Companion Diagnostic
Our specialization and expertise in Companion Diagnostics has evolved over the last twenty years through partnering with renowned international vendors, research institutes and reference centers that seek the breakthroughs in monitoring disease status hence targeting personalized therapeutics.
OncoTect iO™ - IncellDx
IncellDx has launched the CE-IVD marked OncoTect iO Lung kit, a flow cytometry based assay. The kit incorporates a non-enzymatic single cell tissue homogenization process, using incellPREP, for unfixed tumor biopsy samples, labels cell suspensions with antibodies to CD45, CD8, CD3, PD-L1, stained with a Cell Cycle Dye, and then analyzes samples via flow cytometry. This allows researchers to enumerate the immune and tumor cell populations, quantify the percent of cells expressing PD-L1, and quantify PD-L1 receptor expression across each cell type. The assay also quantifies tumor infiltrating lymphocytes and quantification of PD-L1 expression at various stages of the tumor cell cycle.
FEMTELLE® uPA/PAI-1 - FEMTELLE®
Chemotherapy: YES or NO? The FEMTELLE® uPA/PAI-1 Test helps to make informed treatment decisions The FEMTELLE® uPA/PAI-1 Assay is included in German and American guidelines. The test helps to assess risk of disease recurrence in primary breast cancer and predicts chemotherapy benefit after breast cancer surgery. The FEMTELLE® uPA/PAI-1 Assay indicates if chemotherapy is, in fact necessary and helps to predict chemotherapy benefit after surgery.
Quantum Blue® Infliximab - buhlmann
The biologic drug Infliximab is a therapeutic monoclonal antibody. It acts as is an antagonist to TNF alpha, thus is effective in blocking the inflammatory process in numerous chronic inflammatory diseases like Crohn’s disease, ulcerative colitis and inflammatory arthritis. The BÜHLMANN Quantum Blue® Infliximab is the first rapid test to measure infliximab trough level in patient’s serum to allow immediate decision making for potential drug dose adjustments.
Cell-based assays (iLite®) - Euro Diagnostica
iLite technology is based upon a reporter gene assay format, modified and adapted for applications during the whole drug development cycle as well as for monitoring of biological drugs.